193 related articles for article (PubMed ID: 24897141)
1. Bullous pemphigoid treated with intravenous immunoglobulin.
Tuchinda P; Ritchie S; Gaspari AA
Cutis; 2014 May; 93(5):264-8. PubMed ID: 24897141
[TBL] [Abstract][Full Text] [Related]
2. Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: A retrospective study with a 6-year follow-up.
Ahmed AR; Shetty S; Kaveri S; Spigelman ZS
J Am Acad Dermatol; 2016 Apr; 74(4):700-8.e3. PubMed ID: 26851830
[TBL] [Abstract][Full Text] [Related]
3. "Half-half" blisters in bullous pemphigoid successfully treated with adjuvant high-dose intravenous immunoglobulin.
Pacheco D; Lopes L; Soares-Almeida L; Marques MS; Filipe P
Acta Dermatovenerol Alp Pannonica Adriat; 2012 Sep; 21(3):59-61. PubMed ID: 23267874
[TBL] [Abstract][Full Text] [Related]
4. Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events.
Seidling V; Hoffmann JH; Enk AH; Hadaschik EN
Acta Derm Venereol; 2013 May; 93(3):346-9. PubMed ID: 23073990
[TBL] [Abstract][Full Text] [Related]
5. Infantile Bullous Pemphigoid Treated Using Intravenous Immunoglobulin: Case Report and Review of the Literature.
Tekin B; Yücelten AD
Pediatr Dermatol; 2015; 32(5):723-6. PubMed ID: 26119800
[TBL] [Abstract][Full Text] [Related]
6. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment.
Ahmed AR
J Am Acad Dermatol; 2001 Dec; 45(6):825-35. PubMed ID: 11712025
[TBL] [Abstract][Full Text] [Related]
7. Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodies.
Czernik A; Bystryn JC
Arch Dermatol; 2008 May; 144(5):658-61. PubMed ID: 18490594
[TBL] [Abstract][Full Text] [Related]
8. High-dose intravenous immunoglobulin in the treatment of adult patients with bullous pemphigoid.
Gaitanis G; Alexis I; Pelidou SH; Gazi IF; Kyritsis AP; Elisaf MS; Bassukas ID
Eur J Dermatol; 2012; 22(3):363-9. PubMed ID: 22548754
[TBL] [Abstract][Full Text] [Related]
9. Infantile bullous pemphigoid successfully treated with combined pulse corticosteroids and high-dose IVIG.
Wawrzycki B; Krasowska D; Pietrzak A; Szumilo J; Blazowski L; Pietraszek-Mamcarz J; Lotti T
Dermatol Ther; 2018 Sep; 31(5):e12635. PubMed ID: 30216603
[TBL] [Abstract][Full Text] [Related]
10. Positive clinical outcome with IVIg as monotherapy in recurrent pemphigoid gestationis.
Nguyen T; Alraqum E; Razzaque Ahmed A
Int Immunopharmacol; 2015 May; 26(1):1-3. PubMed ID: 25765353
[TBL] [Abstract][Full Text] [Related]
11. Infantile bullous pemphigoid treated with intravenous immunoglobulin therapy.
Sugawara N; Nagai Y; Matsushima Y; Aoyama K; Ishikawa O
J Am Acad Dermatol; 2007 Dec; 57(6):1084-9. PubMed ID: 17889964
[TBL] [Abstract][Full Text] [Related]
12. Case of bullous pemphigoid who achieved a long-term remission by a single course of high-dose i.v. immunoglobulin monotherapy.
Yu Y; Furuta J; Watanabe R; Inoue S; Nakamura Y; Ishitsuka Y; Okiyama N; Ishii Y; Fujisawa Y
J Dermatol; 2020 Jun; 47(6):e225-e227. PubMed ID: 32207163
[No Abstract] [Full Text] [Related]
13. Infantile bullous pemphigoid successfully treated with i.v. immunoglobulin and cyclosporin.
Okada K; Kakeda M; Yamamoto S; Yokoyama T; Habe K; Nakato D; Hirayama M; Mizutani H; Yamanaka K
J Dermatol; 2019 Jun; 46(6):e213-e214. PubMed ID: 30536915
[No Abstract] [Full Text] [Related]
14. Trends in mortality and morbidity in patients with bullous pemphigoid before and after approval of intravenous immunoglobulin in Japan: an interrupted time-series analysis.
Miyachi H; Konishi T; Hashimoto Y; Matsui H; Fushimi K; Inozume T; Matsue H; Yasunaga H
Clin Exp Dermatol; 2023 Jun; 48(6):667-673. PubMed ID: 36891872
[TBL] [Abstract][Full Text] [Related]
15. Postvaccinal, corticosteroid-resistant bullous pemphigoid in infancy: treatment with intravenous immunoglobulin.
Ister M; Pouessel G; Ythier H; Catteau B; Carpentier O
Pediatr Dermatol; 2014; 31(4):e94-5. PubMed ID: 24916151
[TBL] [Abstract][Full Text] [Related]
16. Bullous pemphigoid treatment review.
Patton T; Korman NJ
Expert Opin Pharmacother; 2006 Dec; 7(17):2403-11. PubMed ID: 17109614
[TBL] [Abstract][Full Text] [Related]
17. A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid.
Amagai M; Ikeda S; Hashimoto T; Mizuashi M; Fujisawa A; Ihn H; Matsuzaki Y; Ohtsuka M; Fujiwara H; Furuta J; Tago O; Yamagami J; Tanikawa A; Uhara H; Morita A; Nakanishi G; Tani M; Aoyama Y; Makino E; Muto M; Manabe M; Konno T; Murata S; Izaki S; Watanabe H; Yamaguchi Y; Matsukura S; Seishima M; Habe K; Yoshida Y; Kaneko S; Shindo H; Nakajima K; Kanekura T; Takahashi K; Kitajima Y; Hashimoto K;
J Dermatol Sci; 2017 Feb; 85(2):77-84. PubMed ID: 27876358
[TBL] [Abstract][Full Text] [Related]
18. Bullous Pemphigoid Successfully Treated With a Combination Therapy of Plasmapheresis Followed by Intravenous High Dose Immunoglobulin.
Hattori Y; Takahashi T; Seishima M
Ther Apher Dial; 2017 Aug; 21(4):421-423. PubMed ID: 28378368
[No Abstract] [Full Text] [Related]
19. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases.
Daoud YJ; Amin KG
Int Immunopharmacol; 2006 Apr; 6(4):600-6. PubMed ID: 16504922
[TBL] [Abstract][Full Text] [Related]
20. Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: analysis of current data.
Engineer L; Ahmed AR
J Am Acad Dermatol; 2001 Jan; 44(1):83-8. PubMed ID: 11148470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
